There are 413 resources available
5P - HER2DX risk-score in HER2-positive (HER2+) breast cancer following neoadjuvant and adjuvant anti-HER2-based treatment: an updated survival analysis
Presenter: Olga Martinez Saez
Session: Poster viewing and lunch
6P - Combined analysis of the HER2DX genomic tool in adjuvant APT and ATEMPT trials
Presenter: Paolo Tarantino
Session: Poster viewing and lunch
7P - Independent validation of HER2DX ERBB2 mRNA score to predict HER2-positive (HER2+), HER2-low and HER2-0 status in breast cancer
Presenter: Esther Sanfeliu Torres
Session: Poster viewing and lunch
8P - First decision impact study of HER2DX in patients (pts) with HER2-positive (HER2+) early breast cancer
Presenter: Olga Martinez Saez
Session: Poster viewing and lunch
9P - Prognostic Value of Baseline Neutrophil/Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer: Exploratory analysis from the CLEOPATRA trial
Presenter: Zhi Xiao
Session: Poster viewing and lunch
10P - HER2 loss and PAM50 dynamics after neoadjuvant therapy (NAT) in HER2 positive (HER2+) early breast cancer (BC)
Presenter: Stefania Morganti
Session: Poster viewing and lunch
11P - Independent validation of the HER2DX assay in HER2-positive (HER2+) breast cancer (BC) treated with neoadjuvant paclitaxel, trastuzumab and pertuzumab (THP): a correlative analysis from the BiOnHER study
Presenter: Bartomeu Fullana Grimalt
Session: Poster viewing and lunch
12P - HER2DX in HER2-positive (HER2+) Inflammatory Breast Cancer (IBC): a correlative analysis from a phase II clinical trial
Presenter: Adrienne Waks
Session: Poster viewing and lunch
13P - Analytical validation of HER2DX test for early-her2+ breast cancer
Presenter: Esther Sanfeliu Torres
Session: Poster viewing and lunch
14P - Comparison of single-cell ERBB2 mRNA expression levels with HER2 status by immunohistochemistry reveals heterogeneity of the HER2-low status
Presenter: François Richard
Session: Poster viewing and lunch